Table 6.
Change in myocardial FDG uptake during chemotherapy
| Baseline PET | Follow-up PET | p value | ||
|---|---|---|---|---|
| Interim | Final | |||
| Positive myocardial uptake (n) | 26 (43.3 %) | 38 (63.3 %) | 39 (65.0 %) | 0.008a |
| SUVmax (range) | 2.8–17.8 | 2.8–16.9 | 2.5–11.4 | |
| Total myocardium MTV, cm3 (mean ± SD) | 107.49 ± 173.91 | 147.51 ± 169.51 | 118.95 ± 133.49 | 0.289b |
| Total myocardium TLG, cm3 (mean ± SD) | 382.73 ± 699.67 | 474.18 ± 662.61 | 360.24 ± 441.48 | 0.337b |
| LV MTV, cm3 (mean ± SD) | 98.02 ± 149.22 | 138.35 ± 151.44 | 116.06 ± 129.38 | 0.183b |
| LV TLG, cm3 (mean ± SD) | 366.72 ± 661.52 | 456.85 ± 618.28 | 355.35 ± 434.60 | 0.378b |
aChi-square test, brepeated measures ANOVA
MTV metabolic tumor volume, TLG total lesion glycolysis, LV left ventricle